{"id": "article-131512_0", "title": "Non-Dieting Approaches to Treatment of Obesity -- Continuing Education Activity", "content": "Obesity is a serious global pandemic that requires prompt interventions to avoid the development of complications. While diet and exercise interventions are always discussed first, drug therapy, bariatric surgery, and new gastrointestinal devices can aid patients in achieving weight loss to improve cardiometabolic outcomes. This activity describes in detail the available therapies, beyond dieting, to treat obesity and helps the interprofessional team initiate early treatment, taking into account their patient's preferences.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Continuing Education Activity. Obesity is a serious global pandemic that requires prompt interventions to avoid the development of complications. While diet and exercise interventions are always discussed first, drug therapy, bariatric surgery, and new gastrointestinal devices can aid patients in achieving weight loss to improve cardiometabolic outcomes. This activity describes in detail the available therapies, beyond dieting, to treat obesity and helps the interprofessional team initiate early treatment, taking into account their patient's preferences."}
{"id": "article-131512_1", "title": "Non-Dieting Approaches to Treatment of Obesity -- Continuing Education Activity", "content": "Objectives: Identify the neurochemicals, hormones, and signals involved in the homeostatic and hedonistic pathways, which serve as weight loss medication targets. Review the drug therapies that are currently FDA approved and pharmacotherapy that is being developed to treat obesity. Describe the gastrointestinal devices that are approved by the FDA for the treatment of obesity. Summarize the available bariatric surgery techniques performed by an interprofessional team to treat obesity. Access free multiple choice questions on this topic.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Continuing Education Activity. Objectives: Identify the neurochemicals, hormones, and signals involved in the homeostatic and hedonistic pathways, which serve as weight loss medication targets. Review the drug therapies that are currently FDA approved and pharmacotherapy that is being developed to treat obesity. Describe the gastrointestinal devices that are approved by the FDA for the treatment of obesity. Summarize the available bariatric surgery techniques performed by an interprofessional team to treat obesity. Access free multiple choice questions on this topic."}
{"id": "article-131512_2", "title": "Non-Dieting Approaches to Treatment of Obesity -- Introduction", "content": "A\u00a0body mass index of\u00a0\u226530 (>27 in those of Asian descent) kilograms per square meter constitutes the definition of obesity. [1] Obesity involves a complex interplay of genetic, sociocultural, environmental, and behavioral factors. In 1997, the World Health Organization (WHO) declared obesity a major global health issue along with undernutrition and climate change-the triad being termed \"the Global Syndemic.\" [2] Today in the United States of America (USA), one-third of the adult population is obese, with the Center for Disease Control\u00a0projecting that by 2050 60% of men and 40% of women in the USA will be obese. [3]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Introduction. A\u00a0body mass index of\u00a0\u226530 (>27 in those of Asian descent) kilograms per square meter constitutes the definition of obesity. [1] Obesity involves a complex interplay of genetic, sociocultural, environmental, and behavioral factors. In 1997, the World Health Organization (WHO) declared obesity a major global health issue along with undernutrition and climate change-the triad being termed \"the Global Syndemic.\" [2] Today in the United States of America (USA), one-third of the adult population is obese, with the Center for Disease Control\u00a0projecting that by 2050 60% of men and 40% of women in the USA will be obese. [3]"}
{"id": "article-131512_3", "title": "Non-Dieting Approaches to Treatment of Obesity -- Introduction", "content": "Obesity once again came into focus during the SARS-CoV-2 pandemic, when\u00a0patients with obesity were found to have an increased need for mechanical ventilation and higher mortality. [4] Once thought to be an exclusive problem of the developed\u00a0world, numerous studies have shown developing countries now\u00a0have the highest incidence of obesity. South-East Asians have a higher percentage of body fat,\u00a0truncal/central obesity, and insulin resistance than their\u00a0White race counterparts prompting the WHO to endorse a lower cut-off point for action against obesity at\u00a0\u226527kg/m^2 in the Asian population. [5] The latest terminology introduced for obesity is ABCD-adiposity based chronic disease, which shifts the focus to the chronic nature of obesity and its comorbidities, which require treatment in addition to\u00a0the treatment\u00a0of obesity itself. [6]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Introduction. Obesity once again came into focus during the SARS-CoV-2 pandemic, when\u00a0patients with obesity were found to have an increased need for mechanical ventilation and higher mortality. [4] Once thought to be an exclusive problem of the developed\u00a0world, numerous studies have shown developing countries now\u00a0have the highest incidence of obesity. South-East Asians have a higher percentage of body fat,\u00a0truncal/central obesity, and insulin resistance than their\u00a0White race counterparts prompting the WHO to endorse a lower cut-off point for action against obesity at\u00a0\u226527kg/m^2 in the Asian population. [5] The latest terminology introduced for obesity is ABCD-adiposity based chronic disease, which shifts the focus to the chronic nature of obesity and its comorbidities, which require treatment in addition to\u00a0the treatment\u00a0of obesity itself. [6]"}
{"id": "article-131512_4", "title": "Non-Dieting Approaches to Treatment of Obesity -- Introduction", "content": "It is well known that obesity is associated with a shortened life span and\u00a0increased incidence of obstructive sleep apnea, osteoarthritis, gout, polycystic ovarian syndrome, metabolic syndrome, prediabetes, hypertension, stroke, non-alcoholic fatty liver disease, heart failure, and cancers of the colon, breast, endometrium, and gallbladder. [7] Thus the treatment of obesity is essential, along with early identification of complications. Although this article focuses on non-dieting approaches to treating obesity with medications, gastrointestinal devices, and bariatric surgery, it must be emphasized that diet and exercise are essential to good cardiometabolic health in obese patients.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Introduction. It is well known that obesity is associated with a shortened life span and\u00a0increased incidence of obstructive sleep apnea, osteoarthritis, gout, polycystic ovarian syndrome, metabolic syndrome, prediabetes, hypertension, stroke, non-alcoholic fatty liver disease, heart failure, and cancers of the colon, breast, endometrium, and gallbladder. [7] Thus the treatment of obesity is essential, along with early identification of complications. Although this article focuses on non-dieting approaches to treating obesity with medications, gastrointestinal devices, and bariatric surgery, it must be emphasized that diet and exercise are essential to good cardiometabolic health in obese patients."}
{"id": "article-131512_5", "title": "Non-Dieting Approaches to Treatment of Obesity -- Function", "content": "Obesity is a disease of prolonged positive energy balance. It has been long studied that the body actively defends adiposity as an adaptive survival mechanism; attempts to lose weight must be at least partially uncoupled from counter-regulatory or compensatory mechanisms to increase food intake. This can be\u00a0achieved via medications\u00a0and\u00a0cognitive behavioral therapy. The hypothalamus is the center of the homeostatic pathways and functions as a master energy sensor. Additionally, hedonistic counterregulatory/compensatory mechanisms involve the senses and\u00a0specific areas of the\u00a0brain, which are significantly different in their level of functioning between obese and lean people. The table below lists hormones, neurochemicals, and signals involved in this complex circuitry that governs food intake. Understanding these pathways is important as researchers\u00a0continue to devise weight loss drugs that target these\u00a0neurochemicals. [1] [8]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Function. Obesity is a disease of prolonged positive energy balance. It has been long studied that the body actively defends adiposity as an adaptive survival mechanism; attempts to lose weight must be at least partially uncoupled from counter-regulatory or compensatory mechanisms to increase food intake. This can be\u00a0achieved via medications\u00a0and\u00a0cognitive behavioral therapy. The hypothalamus is the center of the homeostatic pathways and functions as a master energy sensor. Additionally, hedonistic counterregulatory/compensatory mechanisms involve the senses and\u00a0specific areas of the\u00a0brain, which are significantly different in their level of functioning between obese and lean people. The table below lists hormones, neurochemicals, and signals involved in this complex circuitry that governs food intake. Understanding these pathways is important as researchers\u00a0continue to devise weight loss drugs that target these\u00a0neurochemicals. [1] [8]"}
{"id": "article-131512_6", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern", "content": "Even though lifestyle modification via diet, exercise, and behavioral therapy\u00a0is considered the primary treatment of obesity,\u00a0most people cannot achieve or maintain weight loss without the help of pharmacotherapy or surgery. Since 2013 many professional societies for Internal Medicine, Obesity, Endocrinology, and Cardiology have endorsed pharmacotherapy for patients with a BMI of \u226530 or \u226527 with obesity-related complications who were struggling to achieve their weight goals with diet and exercise. However, this guideline was promptly furthered in 2016 to endorse pharmacotherapy as a first-line treatment for weight loss in patients with severe obesity-related comorbidities, even without the criteria of failing lifestyle modification. [7] The Asia Pacific obesity guidelines endorse drug therapy for patients with a BMI of \u226525 or \u226523 with weight-related complications in Asian populations. [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern. Even though lifestyle modification via diet, exercise, and behavioral therapy\u00a0is considered the primary treatment of obesity,\u00a0most people cannot achieve or maintain weight loss without the help of pharmacotherapy or surgery. Since 2013 many professional societies for Internal Medicine, Obesity, Endocrinology, and Cardiology have endorsed pharmacotherapy for patients with a BMI of \u226530 or \u226527 with obesity-related complications who were struggling to achieve their weight goals with diet and exercise. However, this guideline was promptly furthered in 2016 to endorse pharmacotherapy as a first-line treatment for weight loss in patients with severe obesity-related comorbidities, even without the criteria of failing lifestyle modification. [7] The Asia Pacific obesity guidelines endorse drug therapy for patients with a BMI of \u226525 or \u226523 with weight-related complications in Asian populations. [2]"}
{"id": "article-131512_7", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern", "content": "Based on the 2007 FDA guidelines, any drug marketed for the treatment of obesity must produce a \u22655% weight reduction in at least 35% of the subjects studied in the trial with actual reduction of body fat measured by dual-energy absorptiometry and simultaneously demonstrate cardiovascular safety with improvements in metabolic parameters, such as lipid profile and blood pressure. In addition, all drugs have to undergo pre-marketing testing to ensure that they do not increase cardiovascular disease risk. The weight lost at the 12-week mark is considered an indicator of response to a particular drug. If adherence to the drug can be ensured and weight loss of 5% is not achieved in 12 weeks, the dose of the drug can be increased, combined with another drug, stopped altogether, or a new drug can be started. Obesity must be considered a chronic condition requiring long-term treatment as most patients who stop pharmacotherapy are prone to rebound weight gain. If lifestyle modification and drug therapy fail, bariatric surgery must be considered a sustainable weight loss option. [8] [3] [9]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern. Based on the 2007 FDA guidelines, any drug marketed for the treatment of obesity must produce a \u22655% weight reduction in at least 35% of the subjects studied in the trial with actual reduction of body fat measured by dual-energy absorptiometry and simultaneously demonstrate cardiovascular safety with improvements in metabolic parameters, such as lipid profile and blood pressure. In addition, all drugs have to undergo pre-marketing testing to ensure that they do not increase cardiovascular disease risk. The weight lost at the 12-week mark is considered an indicator of response to a particular drug. If adherence to the drug can be ensured and weight loss of 5% is not achieved in 12 weeks, the dose of the drug can be increased, combined with another drug, stopped altogether, or a new drug can be started. Obesity must be considered a chronic condition requiring long-term treatment as most patients who stop pharmacotherapy are prone to rebound weight gain. If lifestyle modification and drug therapy fail, bariatric surgery must be considered a sustainable weight loss option. [8] [3] [9]"}
{"id": "article-131512_8", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- I) Drugs of historical significance/withdrawn from the market for the treatment of obesity", "content": "Thyroid hormone, dinitrophenol, amphetamines, aminorex, phenylpropanolamine, and ephedra alkaloids were used in the past for weight loss\u00a0but subsequently withdrawn by the FDA for this specific indication due to side effects of sympathetic overactivity. Fenfluramine and dexfenfluramine were banned due to their association with heart disease. Rimonabant, a cannabinoid receptor 1 antagonist/inverse agonist, was also banned as it was associated with depression and suicide. Sibutramine was associated with a high risk of cardiovascular disease and stroke. Lorcaserin was the latest drug to be withdrawn from the market by the FDA in February 2020 after the CAMELLIA-TIMI 61 trial showed that patients who were treated with lorcaserin long-term were at high risk of pancreatic, colorectal, and lung cancers. [9] [1] [7] [10]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- I) Drugs of historical significance/withdrawn from the market for the treatment of obesity. Thyroid hormone, dinitrophenol, amphetamines, aminorex, phenylpropanolamine, and ephedra alkaloids were used in the past for weight loss\u00a0but subsequently withdrawn by the FDA for this specific indication due to side effects of sympathetic overactivity. Fenfluramine and dexfenfluramine were banned due to their association with heart disease. Rimonabant, a cannabinoid receptor 1 antagonist/inverse agonist, was also banned as it was associated with depression and suicide. Sibutramine was associated with a high risk of cardiovascular disease and stroke. Lorcaserin was the latest drug to be withdrawn from the market by the FDA in February 2020 after the CAMELLIA-TIMI 61 trial showed that patients who were treated with lorcaserin long-term were at high risk of pancreatic, colorectal, and lung cancers. [9] [1] [7] [10]"}
{"id": "article-131512_9", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- II) Drugs approved by the FDA for a short term, i.e., \u226412 weeks for treatment of obesity", "content": "These drugs are amphetamine analogs that increase central adrenergic and dopaminergic\u00a0activity to induce weight loss. Unfortunately, they have multiple potential side effects of sympathetic overactivity, including agitation, irritability, hallucinations, nausea, and vomiting. They are contraindicated in patients with hypertension and hyperthyroidism as well as pregnant women. Amphetamine analog examples include phentermine (the most prescribed weight loss drug in the USA) at a dose of 15 to 37.5mg per day, diethylpropion 25 mg three times daily or 75mg extended-release daily, phendimetrazine 17.5mg to 70 mg two to three times a day, and benzphetamine 25mg to 50mg once to three times per day. [7] [9] [1] [3]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- II) Drugs approved by the FDA for a short term, i.e., \u226412 weeks for treatment of obesity. These drugs are amphetamine analogs that increase central adrenergic and dopaminergic\u00a0activity to induce weight loss. Unfortunately, they have multiple potential side effects of sympathetic overactivity, including agitation, irritability, hallucinations, nausea, and vomiting. They are contraindicated in patients with hypertension and hyperthyroidism as well as pregnant women. Amphetamine analog examples include phentermine (the most prescribed weight loss drug in the USA) at a dose of 15 to 37.5mg per day, diethylpropion 25 mg three times daily or 75mg extended-release daily, phendimetrazine 17.5mg to 70 mg two to three times a day, and benzphetamine 25mg to 50mg once to three times per day. [7] [9] [1] [3]"}
{"id": "article-131512_10", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- III) Drugs approved by the FDA for the long-term treatment of obesity", "content": "The FDA approved 5 drugs for the long-term\u00a0treatment of obesity in the general population, as listed below. All five drugs have been studied in detail with multiple trials for efficacy, safety, and cardiometabolic benefits as per the FDA mandate. Below is a detailed mechanism of action, year of FDA approval, important trials that proved their benefits, approximate weight loss, dosing, contraindications, precautions, adverse effects, and important facts related to each drug.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- III) Drugs approved by the FDA for the long-term treatment of obesity. The FDA approved 5 drugs for the long-term\u00a0treatment of obesity in the general population, as listed below. All five drugs have been studied in detail with multiple trials for efficacy, safety, and cardiometabolic benefits as per the FDA mandate. Below is a detailed mechanism of action, year of FDA approval, important trials that proved their benefits, approximate weight loss, dosing, contraindications, precautions, adverse effects, and important facts related to each drug."}
{"id": "article-131512_11", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Orlistat", "content": "Mechanism of action:\u00a0Gastric and pancreatic lipase inhibitor Year of FDA approval:\u00a01999 Important trials:\u00a0XENDOS Approximate weight loss in % total body weight: 3 Dosing: Over the counter: Oral 60mg three times daily with meals Prescription-strength: 120mg three times daily with meals Contraindications: Pregnancy, malabsorption syndrome, cholestasis Precautions: The patient should be on a multivitamin and\u00a0fiber supplement Adverse Events: Flatus, fecal incontinence, steatorrhea, increased chances of renal oxalate stones Important facts: It is the only anti-obesity drug approved for adolescents [8] [3] [7] [11] [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Orlistat. Mechanism of action:\u00a0Gastric and pancreatic lipase inhibitor Year of FDA approval:\u00a01999 Important trials:\u00a0XENDOS Approximate weight loss in % total body weight: 3 Dosing: Over the counter: Oral 60mg three times daily with meals Prescription-strength: 120mg three times daily with meals Contraindications: Pregnancy, malabsorption syndrome, cholestasis Precautions: The patient should be on a multivitamin and\u00a0fiber supplement Adverse Events: Flatus, fecal incontinence, steatorrhea, increased chances of renal oxalate stones Important facts: It is the only anti-obesity drug approved for adolescents [8] [3] [7] [11] [2]"}
{"id": "article-131512_12", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Mechanism of action: GLP-1 agonist: direct stimulation of pro-opiomelanocortin (POMC), amphetamine-regulated transcript, indirectly inhibition of NPY, delays gastric emptying, promotes satiety", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Mechanism of action: GLP-1 agonist: direct stimulation of pro-opiomelanocortin (POMC), amphetamine-regulated transcript, indirectly inhibition of NPY, delays gastric emptying, promotes satiety"}
{"id": "article-131512_13", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Year of FDA approval:\u00a02015", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Year of FDA approval:\u00a02015"}
{"id": "article-131512_14", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Important trials:\u00a0SCALE-Sleep apnea, SCALE-diabetes, SCALE-obesity and prediabetes, SCALE-maintenance, LEADER", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Important trials:\u00a0SCALE-Sleep apnea, SCALE-diabetes, SCALE-obesity and prediabetes, SCALE-maintenance, LEADER"}
{"id": "article-131512_15", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Approximate weight loss in % total body weight:\u00a04 to 5.4", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Approximate weight loss in % total body weight:\u00a04 to 5.4"}
{"id": "article-131512_16", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Dosing:\u00a00.6 mg subcutaneous (SQ) per day and up titrate every week to 3mg SQ daily", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Dosing:\u00a00.6 mg subcutaneous (SQ) per day and up titrate every week to 3mg SQ daily"}
{"id": "article-131512_17", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Contraindications: Pregnancy, multiple endocrine neoplasias (MEN)-2 syndrome, a personal/family history of medullary carcinoma of the thyroid, acute or chronic pancreatitis", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Contraindications: Pregnancy, multiple endocrine neoplasias (MEN)-2 syndrome, a personal/family history of medullary carcinoma of the thyroid, acute or chronic pancreatitis"}
{"id": "article-131512_18", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Precautions: Can cause concurrent hypoglycemia with insulin or insulin secretagogue", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Precautions: Can cause concurrent hypoglycemia with insulin or insulin secretagogue"}
{"id": "article-131512_19", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Adverse Events:\u00a0Nausea, vomiting, diarrhea, abdominal pain", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Adverse Events:\u00a0Nausea, vomiting, diarrhea, abdominal pain"}
{"id": "article-131512_20", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide", "content": "Important facts: Improves metabolic syndrome, hepatic steatosis, polycystic ovarian syndrome (PCOS), type 2 diabetes (T2DM), cardiovascular disease (CVD), and obstructive sleep apnea (OSA). [8] [1] [3] [7] [11] [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Liraglutide. Important facts: Improves metabolic syndrome, hepatic steatosis, polycystic ovarian syndrome (PCOS), type 2 diabetes (T2DM), cardiovascular disease (CVD), and obstructive sleep apnea (OSA). [8] [1] [3] [7] [11] [2]"}
{"id": "article-131512_21", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Mechanism of action:\u00a0Phentermine=noradrenergic: activates POMC neurons in arcuate nucleus + Topiramate=GABA Agonist, AMPA/Kainate glutamate antagonist", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Mechanism of action:\u00a0Phentermine=noradrenergic: activates POMC neurons in arcuate nucleus + Topiramate=GABA Agonist, AMPA/Kainate glutamate antagonist"}
{"id": "article-131512_22", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Year of FDA approval:\u00a02012", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Year of FDA approval:\u00a02012"}
{"id": "article-131512_23", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Important trials:\u00a0EQUATE, EQUIP, CONQUER, SEQUEL", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Important trials:\u00a0EQUATE, EQUIP, CONQUER, SEQUEL"}
{"id": "article-131512_24", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Approximate weight loss in % total body weight:\u00a08.6 to 9.3", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Approximate weight loss in % total body weight:\u00a08.6 to 9.3"}
{"id": "article-131512_25", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Dosing:\u00a0Phentermine immediate release with Topiramate sustained release: starting 3.75mg-23mg for 2 weeks and escalate to the recommended dose of 7.5mg-46mg. It can be further escalated to a maximum dose of 15mg-92mg daily", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Dosing:\u00a0Phentermine immediate release with Topiramate sustained release: starting 3.75mg-23mg for 2 weeks and escalate to the recommended dose of 7.5mg-46mg. It can be further escalated to a maximum dose of 15mg-92mg daily"}
{"id": "article-131512_26", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Contraindications: Pregnancy, uncontrolled hypertension (HTN), CVD", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Contraindications: Pregnancy, uncontrolled hypertension (HTN), CVD"}
{"id": "article-131512_27", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Precautions: Increased risk of kidney stones, increase in heart rate, suicidal ideation, abrupt withdrawal can trigger seizures", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Precautions: Increased risk of kidney stones, increase in heart rate, suicidal ideation, abrupt withdrawal can trigger seizures"}
{"id": "article-131512_28", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Adverse Events: Paraesthesia, dysgeusia, constipation, metabolic acidosis", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Adverse Events: Paraesthesia, dysgeusia, constipation, metabolic acidosis"}
{"id": "article-131512_29", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate", "content": "Important facts: It is the first combination treatment approved for obesity and the most effective in causing weight loss. It is a category X drug increasing the chances of cleft lip in the fetus. Risk Evaluation and Mitigation Strategies (REMS) program recommend pregnancy tests before initiating the drug and monthly pregnancy tests\u00a0while on the medication. [8] [1] [3] [7] [11] [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Phentermine + Topiramate. Important facts: It is the first combination treatment approved for obesity and the most effective in causing weight loss. It is a category X drug increasing the chances of cleft lip in the fetus. Risk Evaluation and Mitigation Strategies (REMS) program recommend pregnancy tests before initiating the drug and monthly pregnancy tests\u00a0while on the medication. [8] [1] [3] [7] [11] [2]"}
{"id": "article-131512_30", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4. Naltrexone + Bupropion", "content": "Mechanism of action:\u00a0Naltrexone=opioid antagonist: prevents beta-endorphin mediated negative feedback on alpha MSH + bupropion=inhibitor of DA and NE transporter: Stimulates POMC with increased release of alpha-MSH Year of FDA approval:\u00a02014 Important trials:\u00a0COR-I, COR-II, COR-BMOD, COR-Diabetes, LIGHT Approximate weight loss in % total body weight:\u00a03.3 to 4.8 Dosing:\u00a0Sustained release combination: 8-90 mg daily, up titrated to 16mg-180mg twice daily Contraindications: Pregnancy, seizure disorder, anorexia or bulimia, alcohol withdrawal, age >75 years, use of monoamine oxidase inhibitors within 2 weeks of drug initiation Precautions: Monitor for suicidal ideation, increase in heart rate Adverse Events:\u00a0Nausea, vomiting, dizziness, dry mouth Important facts: Recommended for patients with obesity\u00a0and a concurrent mood disorder. [8] [1] [3] [7] [11] [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4. Naltrexone + Bupropion. Mechanism of action:\u00a0Naltrexone=opioid antagonist: prevents beta-endorphin mediated negative feedback on alpha MSH + bupropion=inhibitor of DA and NE transporter: Stimulates POMC with increased release of alpha-MSH Year of FDA approval:\u00a02014 Important trials:\u00a0COR-I, COR-II, COR-BMOD, COR-Diabetes, LIGHT Approximate weight loss in % total body weight:\u00a03.3 to 4.8 Dosing:\u00a0Sustained release combination: 8-90 mg daily, up titrated to 16mg-180mg twice daily Contraindications: Pregnancy, seizure disorder, anorexia or bulimia, alcohol withdrawal, age >75 years, use of monoamine oxidase inhibitors within 2 weeks of drug initiation Precautions: Monitor for suicidal ideation, increase in heart rate Adverse Events:\u00a0Nausea, vomiting, dizziness, dry mouth Important facts: Recommended for patients with obesity\u00a0and a concurrent mood disorder. [8] [1] [3] [7] [11] [2]"}
{"id": "article-131512_31", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5.\u00a0Semaglutide", "content": "Mechanism of action: GLP-1 agonist with peripheral and central action Year of FDA approval: 2021 Important trials: STEP-1 trial, which compared once-weekly SQ 2.4mg Semaglutide versus placebo in addition to\u00a0lifestyle intervention (individual counseling every 4 weeks, 500 calorie deficit per day, and physical activity for 150 minutes per week) for 68 weeks. Interestingly this trial excluded patients with a history of diabetes. Approximate weight loss: Overall, 14.9% weight reduction, which was statistically significant. Of the participants receiving Semaglutide, 86% had\u00a0\u22655% weight loss, 70%\u00a0had\u00a0\u226510% weight loss, and 50% had at least a 15% weight loss. Dosing: SQ 2.4mg weekly (in the trial, the drug was started at 0.25mg weekly and titrated up to the full dose by week 16) Contraindications: Pregnancy, MEN-2 syndrome, a personal/family history of medullary carcinoma of the thyroid, acute or chronic pancreatitis Adverse effects:\u00a0Diarrhea, nausea, vomiting, cholelithiasis [4]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5.\u00a0Semaglutide. Mechanism of action: GLP-1 agonist with peripheral and central action Year of FDA approval: 2021 Important trials: STEP-1 trial, which compared once-weekly SQ 2.4mg Semaglutide versus placebo in addition to\u00a0lifestyle intervention (individual counseling every 4 weeks, 500 calorie deficit per day, and physical activity for 150 minutes per week) for 68 weeks. Interestingly this trial excluded patients with a history of diabetes. Approximate weight loss: Overall, 14.9% weight reduction, which was statistically significant. Of the participants receiving Semaglutide, 86% had\u00a0\u22655% weight loss, 70%\u00a0had\u00a0\u226510% weight loss, and 50% had at least a 15% weight loss. Dosing: SQ 2.4mg weekly (in the trial, the drug was started at 0.25mg weekly and titrated up to the full dose by week 16) Contraindications: Pregnancy, MEN-2 syndrome, a personal/family history of medullary carcinoma of the thyroid, acute or chronic pancreatitis Adverse effects:\u00a0Diarrhea, nausea, vomiting, cholelithiasis [4]"}
{"id": "article-131512_32", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Setmelanotide", "content": "Mechanism of action: Melanocortin 4 receptor agonist acting on the hypothalamus downstream of the leptin signaling pathway; increases satiety and decreases food consumption Year of FDA approval: November 2020 Specific population: Patients with deficiencies in POMC, PCSK1, or LEPR\u00a0genes (deemed\u00a0pathogenic variants or variants of uncertain significance, confirmed on genetic testing) or with patients with\u00a0Bardet Biedl syndrome Dosing: SQ 2mg daily (maximum dose 3mg daily) Contraindications: Patients with other causes of obesity, polygenic obesity,\u00a0or benign variants of the genetic mutations Adverse effects: Hyperpigmentation, vomiting, nausea [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Setmelanotide. Mechanism of action: Melanocortin 4 receptor agonist acting on the hypothalamus downstream of the leptin signaling pathway; increases satiety and decreases food consumption Year of FDA approval: November 2020 Specific population: Patients with deficiencies in POMC, PCSK1, or LEPR\u00a0genes (deemed\u00a0pathogenic variants or variants of uncertain significance, confirmed on genetic testing) or with patients with\u00a0Bardet Biedl syndrome Dosing: SQ 2mg daily (maximum dose 3mg daily) Contraindications: Patients with other causes of obesity, polygenic obesity,\u00a0or benign variants of the genetic mutations Adverse effects: Hyperpigmentation, vomiting, nausea [2]"}
{"id": "article-131512_33", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Metreleptin", "content": "Mechanism of action: Stimulates POMC neurons and inhibits NPY neurons, thereby increasing energy expenditure and promoting satiety Year of FDA approval: 2014 Specific population: Patients congenital or acquired generalized lipodystrophy with leptin deficiency Adult dosing for weight\u00a0\u226540kg: SQ 2.5mg daily for males and 5mg daily for females (maximum dose 10mg/day) Contraindications: Partial lipodystrophy, established metabolic diseases like type 2 diabetes with lipodystrophy, HIV related lipodystrophy Adverse effects: It can cause pancreatitis, generation of leptin neutralizing antibodies, abdominal pain, and headache.\u00a0Hence it is monitored under the REMS program. [11] [9] [12]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Metreleptin. Mechanism of action: Stimulates POMC neurons and inhibits NPY neurons, thereby increasing energy expenditure and promoting satiety Year of FDA approval: 2014 Specific population: Patients congenital or acquired generalized lipodystrophy with leptin deficiency Adult dosing for weight\u00a0\u226540kg: SQ 2.5mg daily for males and 5mg daily for females (maximum dose 10mg/day) Contraindications: Partial lipodystrophy, established metabolic diseases like type 2 diabetes with lipodystrophy, HIV related lipodystrophy Adverse effects: It can cause pancreatitis, generation of leptin neutralizing antibodies, abdominal pain, and headache.\u00a0Hence it is monitored under the REMS program. [11] [9] [12]"}
{"id": "article-131512_34", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- V) Of note, certain medications FDA approved for other indications (depression, seizure disorder, and type 2 diabetes) can cause weight loss as a side effect", "content": "These include fluoxetine, zonisamide, pramlintide, lixisenatide, dulaglutide, empagliflozin, ertugliflozin, remogliflozin, sergliflozin, metformin, exenatide, canagliflozin, dapagliflozin, octreotide, mirabegron, tadalafil, or bupropion alone. These are not to be prescribed routinely to patients for the indication of weight loss. [3] [11]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- V) Of note, certain medications FDA approved for other indications (depression, seizure disorder, and type 2 diabetes) can cause weight loss as a side effect. These include fluoxetine, zonisamide, pramlintide, lixisenatide, dulaglutide, empagliflozin, ertugliflozin, remogliflozin, sergliflozin, metformin, exenatide, canagliflozin, dapagliflozin, octreotide, mirabegron, tadalafil, or bupropion alone. These are not to be prescribed routinely to patients for the indication of weight loss. [3] [11]"}
{"id": "article-131512_35", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Mechanism of action: Commonly known as the \"twincretin\" due to its dual agonistic action on the incretins-Gastric Inhibitory Peptide (GIP) and GLP-1, which increase insulin response to oral glucose", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Mechanism of action: Commonly known as the \"twincretin\" due to its dual agonistic action on the incretins-Gastric Inhibitory Peptide (GIP) and GLP-1, which increase insulin response to oral glucose"}
{"id": "article-131512_36", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Important trials: SURPASS trials, which have compared tirzepatide to placebo, metformin, semaglutide, dulaglutide, other oral anti-hyperglycemic agents, and Insulin in various combinations, SURMOUNT-1 trial.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Important trials: SURPASS trials, which have compared tirzepatide to placebo, metformin, semaglutide, dulaglutide, other oral anti-hyperglycemic agents, and Insulin in various combinations, SURMOUNT-1 trial."}
{"id": "article-131512_37", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Controversies surrounding the drug and trials: Some studies have shown that GIP is, in fact, obesogenic and there have been GIP antagonists developed to tackle obesity. GIP itself can contribute to hyperglycemia because of the stimulation of glucagon and can inhibit the effect of GLP-1 on decreasing food intake. Hence at least per laboratory data, using a GIP agonist is of limited utility. However, the trial investigators argue that GIP contributes more to the incretin effect than GLP-1, and GIP-induced weight loss is via glucagon's anti-lipogenic and anorexic action. Thus having a dual agonist was more effective than a single agent. Another criticism is that the dose of GLP-1 agonists used in the SURPASS trials to show superiority is suboptimal compared to the dose currently being studied to treat obesity.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Controversies surrounding the drug and trials: Some studies have shown that GIP is, in fact, obesogenic and there have been GIP antagonists developed to tackle obesity. GIP itself can contribute to hyperglycemia because of the stimulation of glucagon and can inhibit the effect of GLP-1 on decreasing food intake. Hence at least per laboratory data, using a GIP agonist is of limited utility. However, the trial investigators argue that GIP contributes more to the incretin effect than GLP-1, and GIP-induced weight loss is via glucagon's anti-lipogenic and anorexic action. Thus having a dual agonist was more effective than a single agent. Another criticism is that the dose of GLP-1 agonists used in the SURPASS trials to show superiority is suboptimal compared to the dose currently being studied to treat obesity."}
{"id": "article-131512_38", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Weight loss: With the 15mg dose weekly, tirzepatide has shown 5.1kg weight reduction in Phase-1 trials and 11.3kg weight reduction in phase-2 trials. In the latest data published by Eli Lily, the SURPASS 2 trial comparing once-weekly\u00a0SQ tirzepatide and a 1mg dose of\u00a0SQ Semaglutide in addition to Metformin showed a weight reduction from baseline of 8.5% with the 5mg dose of Tirzepatide, 11% with the 10mg dose, and 13.1% with the 15mg dose which were all statistically significant over Semaglutide 1mg group.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Weight loss: With the 15mg dose weekly, tirzepatide has shown 5.1kg weight reduction in Phase-1 trials and 11.3kg weight reduction in phase-2 trials. In the latest data published by Eli Lily, the SURPASS 2 trial comparing once-weekly\u00a0SQ tirzepatide and a 1mg dose of\u00a0SQ Semaglutide in addition to Metformin showed a weight reduction from baseline of 8.5% with the 5mg dose of Tirzepatide, 11% with the 10mg dose, and 13.1% with the 15mg dose which were all statistically significant over Semaglutide 1mg group."}
{"id": "article-131512_39", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Dosing: SQ 5 to 15mg weekly. (In the SURPASS-2 trial, the drug was started at 2.5mg and titrated up 4 weekly to the desired dose)", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Dosing: SQ 5 to 15mg weekly. (In the SURPASS-2 trial, the drug was started at 2.5mg and titrated up 4 weekly to the desired dose)"}
{"id": "article-131512_40", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide", "content": "Adverse effects: Hypoglycemia with higher doses, nausea, diarrhea, vomiting [13] [14]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Tirzepatide. Adverse effects: Hypoglycemia with higher doses, nausea, diarrhea, vomiting [13] [14]"}
{"id": "article-131512_41", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- Bariatric Surgeries for the Treatment of Obesity", "content": "Bariatric surgeries\u00a0provide a greater and more sustained weight loss than drug therapy. Bariatric surgery can also lead to a longer life expectancy, as shown\u00a0in a recent study. [15] However, it comes at the expense of irreversibility for some procedures and potential long-term complications. In addition, surgical therapy can prompt addiction transfer, the exchange of palatable food reinforcers with alternate addiction-causing agents, such as smoking, illicit drugs, and alcohol. Several procedures are specifically endorsed by the American Society for Metabolic and Bariatric Surgery and are FDA-approved devices that do not require an Institutional Review Board approval before intervention. However, other surgeries and devices do require IRB approval. Below is a comprehensive list of procedures, associated weight loss, and other considerations.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- Bariatric Surgeries for the Treatment of Obesity. Bariatric surgeries\u00a0provide a greater and more sustained weight loss than drug therapy. Bariatric surgery can also lead to a longer life expectancy, as shown\u00a0in a recent study. [15] However, it comes at the expense of irreversibility for some procedures and potential long-term complications. In addition, surgical therapy can prompt addiction transfer, the exchange of palatable food reinforcers with alternate addiction-causing agents, such as smoking, illicit drugs, and alcohol. Several procedures are specifically endorsed by the American Society for Metabolic and Bariatric Surgery and are FDA-approved devices that do not require an Institutional Review Board approval before intervention. However, other surgeries and devices do require IRB approval. Below is a comprehensive list of procedures, associated weight loss, and other considerations."}
{"id": "article-131512_42", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- Bariatric Surgeries for the Treatment of Obesity", "content": "ASBMS=American Society for Metabolic and Bariatric Surgery, NA=not applicable, IRB=Institutional Review Board, Y=Yes, N=No, BMI in kilograms/square meter, ORC=Obesity related complication, GI=gastrointestinal", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- Bariatric Surgeries for the Treatment of Obesity. ASBMS=American Society for Metabolic and Bariatric Surgery, NA=not applicable, IRB=Institutional Review Board, Y=Yes, N=No, BMI in kilograms/square meter, ORC=Obesity related complication, GI=gastrointestinal"}
{"id": "article-131512_43", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "Description: The stomach is divided into the small proximal gastric pouch, anastomosed to an alimentary limb that drains the consumed food. The distal stomach remnant, liver, pancreas, duodenum, and part of the jejunum are anastomosed to the alimentary limb about 75 to 150cm from the gastrojejunostomy.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). Description: The stomach is divided into the small proximal gastric pouch, anastomosed to an alimentary limb that drains the consumed food. The distal stomach remnant, liver, pancreas, duodenum, and part of the jejunum are anastomosed to the alimentary limb about 75 to 150cm from the gastrojejunostomy."}
{"id": "article-131512_44", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "ASBMS endorsed: Y, FDA approved: NA, ASBMS investigational: NA, IRB approval required: N, covered by insurance: Y", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). ASBMS endorsed: Y, FDA approved: NA, ASBMS investigational: NA, IRB approval required: N, covered by insurance: Y"}
{"id": "article-131512_45", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC"}
{"id": "article-131512_46", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "Advantage/mechanism of weight loss: Food restriction, early satiety, increased anorexigenic gut hormones-GLP-1, CCK, PYY, and decreases ghrelin-thus termed 'metabolic surgery.' Sustained weight loss in long-term follow-up studies. Dramatically improves T2DM-part of the treatment algorithm for uncontrolled T2DM with a BMI of \u226535", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). Advantage/mechanism of weight loss: Food restriction, early satiety, increased anorexigenic gut hormones-GLP-1, CCK, PYY, and decreases ghrelin-thus termed 'metabolic surgery.' Sustained weight loss in long-term follow-up studies. Dramatically improves T2DM-part of the treatment algorithm for uncontrolled T2DM with a BMI of \u226535"}
{"id": "article-131512_47", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "Approximate weight loss in % total body weight: 30 to 35, excess weight loss %: 59.7", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). Approximate weight loss in % total body weight: 30 to 35, excess weight loss %: 59.7"}
{"id": "article-131512_48", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB)", "content": "Adverse effects: Marginal ulcers, internal hernia, small bowel obstruction, vitamin and mineral deficiencies [1] [6] [7] [9]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1.\u00a0Roux-en-Y gastric bypass surgery (RNYGB). Adverse effects: Marginal ulcers, internal hernia, small bowel obstruction, vitamin and mineral deficiencies [1] [6] [7] [9]"}
{"id": "article-131512_49", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Sleeve gastrectomy (SG)", "content": "Description: The stomach is converted to a tubular structure \"gastric sleeve,\" with most of the greater curvature resected to decrease its food holding capacity. This procedure can also be done laparoscopically. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Food restriction, early satiety, decreased ghrelin, increases PYY and GLP-1. Less risk of vitamin deficiency and\u00a0can be converted to RNYGB at a later stage if needed. It is the most common bariatric\u00a0surgery\u00a0performed per the latest statistics. Approximate weight loss in % total body weight:\u00a025 to 30, excess weight loss %: 55.5 Adverse effects: Chronic obstructive symptoms, post-operative\u00a0gastroesophageal reflux [1] [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Sleeve gastrectomy (SG). Description: The stomach is converted to a tubular structure \"gastric sleeve,\" with most of the greater curvature resected to decrease its food holding capacity. This procedure can also be done laparoscopically. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Food restriction, early satiety, decreased ghrelin, increases PYY and GLP-1. Less risk of vitamin deficiency and\u00a0can be converted to RNYGB at a later stage if needed. It is the most common bariatric\u00a0surgery\u00a0performed per the latest statistics. Approximate weight loss in % total body weight:\u00a025 to 30, excess weight loss %: 55.5 Adverse effects: Chronic obstructive symptoms, post-operative\u00a0gastroesophageal reflux [1] [6] [7]"}
{"id": "article-131512_50", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Laparoscopic adjustable gastric banding (LAGB)", "content": "Description:\u00a0An adjustable silicone band around the upper stomach is connected to a port in the subcutaneous tissue, which can be used to restrict the food holding capacity of the stomach. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Food restriction, early satiety, the least invasive bariatric procedure, reversible, outpatient procedure Approximate weight loss in % total body weight:\u00a020 to 25, excess weight loss %:\u00a046.2 Adverse effects: Band slippage, erosion, bowel obstruction, dilatation of the esophagus [1] [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3.\u00a0Laparoscopic adjustable gastric banding (LAGB). Description:\u00a0An adjustable silicone band around the upper stomach is connected to a port in the subcutaneous tissue, which can be used to restrict the food holding capacity of the stomach. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Food restriction, early satiety, the least invasive bariatric procedure, reversible, outpatient procedure Approximate weight loss in % total body weight:\u00a020 to 25, excess weight loss %:\u00a046.2 Adverse effects: Band slippage, erosion, bowel obstruction, dilatation of the esophagus [1] [6] [7]"}
{"id": "article-131512_51", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4.\u00a0Biliopancreatic diversion with duodenal switch (BPD/DS)", "content": "Description:\u00a0This procedure involves a sleeve gastrectomy with pylorus attached to an alimentary limb. It also involves a biliopancreatic limb with distal anastomosis of the two limbs and a short common channel running just 50 to 100cm till the ileocaecal valve. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Creates a degree of malabsorption of nutrients, decreases ghrelin. Approximate weight loss in % total body weight: 35 to 45, excess weight loss %: 63.6 Adverse effects: Protein malnutrition, anemia, diarrhea, stomach ulceration, duodenal dissection, the potential for internal hernias [1] [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4.\u00a0Biliopancreatic diversion with duodenal switch (BPD/DS). Description:\u00a0This procedure involves a sleeve gastrectomy with pylorus attached to an alimentary limb. It also involves a biliopancreatic limb with distal anastomosis of the two limbs and a short common channel running just 50 to 100cm till the ileocaecal valve. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: Y Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Creates a degree of malabsorption of nutrients, decreases ghrelin. Approximate weight loss in % total body weight: 35 to 45, excess weight loss %: 63.6 Adverse effects: Protein malnutrition, anemia, diarrhea, stomach ulceration, duodenal dissection, the potential for internal hernias [1] [6] [7]"}
{"id": "article-131512_52", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5.\u00a0Single Anastomosis Duodeno-ileal bypass with Sleeve gastrectomy", "content": "Description: A single end to side anastomosis between the gastric sleeve pouch with preserved pylorus and distal ileum with the division at the level of the duodenum. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Simpler than BPD/DS, strong metabolic effects Approximate weight loss in % total body weight:\u00a035 to 45 Adverse effects: Micronutr deficiencies, duodenal dissection [6]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5.\u00a0Single Anastomosis Duodeno-ileal bypass with Sleeve gastrectomy. Description: A single end to side anastomosis between the gastric sleeve pouch with preserved pylorus and distal ileum with the division at the level of the duodenum. ASBMS endorsed: Y,\u00a0FDA approved: NA,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population:\u00a0BMI \u226540 or \u226535 with 1 ORC Advantage/Mechanism of weight loss: Simpler than BPD/DS, strong metabolic effects Approximate weight loss in % total body weight:\u00a035 to 45 Adverse effects: Micronutr deficiencies, duodenal dissection [6]"}
{"id": "article-131512_53", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 6.\u00a0Primary obesity surgery endoluminal (POSE procedure)", "content": "Description:\u00a0This endoscopic incision-less procedure creates\u00a0full-thickness plications in the gastric fundus and body using anchors that effectively reduce gastric capacity. ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Fewer adverse events compared to other bariatric procedures Approximate weight loss in % total body weight: 5 Adverse effects: Abdominal pain,\u00a0nausea, vomiting [6] [16]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 6.\u00a0Primary obesity surgery endoluminal (POSE procedure). Description:\u00a0This endoscopic incision-less procedure creates\u00a0full-thickness plications in the gastric fundus and body using anchors that effectively reduce gastric capacity. ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Fewer adverse events compared to other bariatric procedures Approximate weight loss in % total body weight: 5 Adverse effects: Abdominal pain,\u00a0nausea, vomiting [6] [16]"}
{"id": "article-131512_54", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 7. Endoscopic sleeve gastroplasty", "content": "Description:\u00a0This endoscopic total gastric thickness suturing system creates a tubular stomach pouch similar to sleeve gastrectomy but without any incisions or laparoscopy. ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Fewer adverse events compared to other bariatric procedures Approximate weight loss in % total body weight: 16 to 20 Adverse effects: No randomized controlled trials documenting the efficacy [6]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 7. Endoscopic sleeve gastroplasty. Description:\u00a0This endoscopic total gastric thickness suturing system creates a tubular stomach pouch similar to sleeve gastrectomy but without any incisions or laparoscopy. ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Fewer adverse events compared to other bariatric procedures Approximate weight loss in % total body weight: 16 to 20 Adverse effects: No randomized controlled trials documenting the efficacy [6]"}
{"id": "article-131512_55", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 8.\u00a0Laparoscopic greater curvature plication", "content": "Description:\u00a0As the name suggests, the gastric sleeve is created by greater curvature plication to itself. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Reversible, no devices or staplers involved Approximate weight loss in % total body weight:\u00a015 to 25 Disadvantages and adverse effects: Difficult to standardize the procedure, dilatation of the stomach [6] [17]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 8.\u00a0Laparoscopic greater curvature plication. Description:\u00a0As the name suggests, the gastric sleeve is created by greater curvature plication to itself. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Reversible, no devices or staplers involved Approximate weight loss in % total body weight:\u00a015 to 25 Disadvantages and adverse effects: Difficult to standardize the procedure, dilatation of the stomach [6] [17]"}
{"id": "article-131512_56", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 9.\u00a0One anastomosis gastric bypass", "content": "Description: This procedure involves a single anastomosis between a tubular gastric pouch (involving the lesser curvature) and the ileum. The remnant stomach and pylorus continue into the duodenum; therefore, the alimentary limb and common channel are essentially the same. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Considered a mini-gastric bypass procedure Approximate weight loss in % total body weight: 35 to 40 Adverse effects: Potential for bile reflux [6] [18]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 9.\u00a0One anastomosis gastric bypass. Description: This procedure involves a single anastomosis between a tubular gastric pouch (involving the lesser curvature) and the ileum. The remnant stomach and pylorus continue into the duodenum; therefore, the alimentary limb and common channel are essentially the same. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Considered a mini-gastric bypass procedure Approximate weight loss in % total body weight: 35 to 40 Adverse effects: Potential for bile reflux [6] [18]"}
{"id": "article-131512_57", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 10.\u00a0Stomach intestinal pylorus sparing-one anastomosis duodenal switch", "content": "Description: This procedure involves a single duodeno-ileostomy with duodenal dissection and transection. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y,\u00a0Covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Simpler than BPD/DS, strong metabolic effects Approximate weight loss in % total body weight: 35 to 45 Adverse effects: Micronutrient deficiencies, duodenal dissection [6] [19]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 10.\u00a0Stomach intestinal pylorus sparing-one anastomosis duodenal switch. Description: This procedure involves a single duodeno-ileostomy with duodenal dissection and transection. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y,\u00a0Covered by insurance: N Patient population: Not specified; general criteria apply Advantage: Simpler than BPD/DS, strong metabolic effects Approximate weight loss in % total body weight: 35 to 45 Adverse effects: Micronutrient deficiencies, duodenal dissection [6] [19]"}
{"id": "article-131512_58", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- A) Intragastric balloons:", "content": "Intragastric balloons can be used for patients with BMI 30 to 40 with 1 ORC. These are typically inserted endoscopically, and the balloon is inflated with 400 to 700cc of saline to reduce gastric capacity,\u00a0promote satiety and delay gastric emptying. Contraindications to their use include hiatal hernia, gastric mass, prior GI surgery, and esophageal motility disorder.\u00a0Adverse effects include GI obstruction/perforation, abdominal pain, and bloating.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- A) Intragastric balloons:. Intragastric balloons can be used for patients with BMI 30 to 40 with 1 ORC. These are typically inserted endoscopically, and the balloon is inflated with 400 to 700cc of saline to reduce gastric capacity,\u00a0promote satiety and delay gastric emptying. Contraindications to their use include hiatal hernia, gastric mass, prior GI surgery, and esophageal motility disorder.\u00a0Adverse effects include GI obstruction/perforation, abdominal pain, and bloating."}
{"id": "article-131512_59", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Orbera-1 balloon", "content": "ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 10.2 [1] [6] [7] [20]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 1. Orbera-1 balloon. ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 10.2 [1] [6] [7] [20]"}
{"id": "article-131512_60", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Obalon-up to 3 balloons", "content": "ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 6.6 [1] [6] [7] [20]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 2. Obalon-up to 3 balloons. ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 6.6 [1] [6] [7] [20]"}
{"id": "article-131512_61", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3. ReShape-2 balloons", "content": "ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 6.8 [1] [6] [7] [21] [20]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 3. ReShape-2 balloons. ASBMS endorsed: Y,\u00a0FDA approved: Y-for 6 months use only,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Approximate weight loss in % total body weight: 6.8 [1] [6] [7] [21] [20]"}
{"id": "article-131512_62", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4. Spatz", "content": "ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Excess weight loss %: 45 to 49 [6] [22] [23]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 4. Spatz. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Excess weight loss %: 45 to 49 [6] [22] [23]"}
{"id": "article-131512_63", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5. Ellipse", "content": "ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Excess weight loss %: 32 [6] [24]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- 5. Ellipse. ASBMS endorsed: N,\u00a0FDA approved: N,\u00a0ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Excess weight loss %: 32 [6] [24]"}
{"id": "article-131512_64", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- B)\u00a0Maestro Rechargeable system-Vagal blockade", "content": "Description: Leads are attached to the anterior and posterior vagal trucks laparoscopically, which cause intermittent vagal blockade\u00a0to induce a sense of satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population: BMI 35 to 45 with 1 ORC Approximate weight loss in % total body weight:\u00a08 to 9 Contraindications: Cirrhosis, portal hypertension, hiatal hernia, patients\u00a0with other implanted devices like permanent pacemakers, and intracardiac defibrillators Adverse effects: Nausea, vomiting, reflux, pain at regulator site [1] [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- B)\u00a0Maestro Rechargeable system-Vagal blockade. Description: Leads are attached to the anterior and posterior vagal trucks laparoscopically, which cause intermittent vagal blockade\u00a0to induce a sense of satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population: BMI 35 to 45 with 1 ORC Approximate weight loss in % total body weight:\u00a08 to 9 Contraindications: Cirrhosis, portal hypertension, hiatal hernia, patients\u00a0with other implanted devices like permanent pacemakers, and intracardiac defibrillators Adverse effects: Nausea, vomiting, reflux, pain at regulator site [1] [6] [7]"}
{"id": "article-131512_65", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- C) Aspire Assist", "content": "Description:\u00a0Directly removes ingested food from the stomach via a port ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population:\u00a0BMI 35 to 55, having failed other treatment modalities Approximate weight loss in % total body weight:\u00a012 to 14 Contraindications: Ulcers, bleeding, gastric masses, eating disorders, cirrhosis Adverse effects: Pain, electrolyte disorders, irritation, infection [1] [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- C) Aspire Assist. Description:\u00a0Directly removes ingested food from the stomach via a port ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population:\u00a0BMI 35 to 55, having failed other treatment modalities Approximate weight loss in % total body weight:\u00a012 to 14 Contraindications: Ulcers, bleeding, gastric masses, eating disorders, cirrhosis Adverse effects: Pain, electrolyte disorders, irritation, infection [1] [6] [7]"}
{"id": "article-131512_66", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- D)\u00a0Transpyloric Bulb Shuttle", "content": "Description: This is a double bulb system inserted endoscopically that slows gastric emptying across the pylorus to induce satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population: Not specified; general criteria apply Approximate weight loss in % total body weight:\u00a014 Adverse effects: Gastric ulcers [6]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- D)\u00a0Transpyloric Bulb Shuttle. Description: This is a double bulb system inserted endoscopically that slows gastric emptying across the pylorus to induce satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N,\u00a0Covered by insurance: N Patient population: Not specified; general criteria apply Approximate weight loss in % total body weight:\u00a014 Adverse effects: Gastric ulcers [6]"}
{"id": "article-131512_67", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- E)\u00a0Gelesis100 (Hydrogel)", "content": "Description: A superabsorbent hydrogel in a swallowed capsule that absorbs water to expand and fill up the stomach to induce satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Approximate weight loss in % total body weight: 6 Adverse effects: Minor GI\u00a0side effects [6] [25]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- E)\u00a0Gelesis100 (Hydrogel). Description: A superabsorbent hydrogel in a swallowed capsule that absorbs water to expand and fill up the stomach to induce satiety ASBMS endorsed: N,\u00a0FDA approved: Y,\u00a0ASBMS investigational: NA,\u00a0IRB approval required: N, covered by insurance: N Patient population: Not specified; general criteria apply Approximate weight loss in % total body weight: 6 Adverse effects: Minor GI\u00a0side effects [6] [25]"}
{"id": "article-131512_68", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- F)\u00a0Endoscopic gastrointestinal bypass devices", "content": "Description: This is a barrier device inserted endoscopically, which extends from the proximal duodenum to the jejunum, effectively simulating a duodenojejunal bypass and promoting rapid weight loss ASBMS endorsed: N,\u00a0FDA approved: N, ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population:\u00a0Not specified; general criteria apply Approximate weight loss in % total body weight: 40 Contraindications and adverse effects: High rate of early removal of the device [6] [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern -- F)\u00a0Endoscopic gastrointestinal bypass devices. Description: This is a barrier device inserted endoscopically, which extends from the proximal duodenum to the jejunum, effectively simulating a duodenojejunal bypass and promoting rapid weight loss ASBMS endorsed: N,\u00a0FDA approved: N, ASBMS investigational: Y,\u00a0IRB approval required: Y, covered by insurance: N Patient population:\u00a0Not specified; general criteria apply Approximate weight loss in % total body weight: 40 Contraindications and adverse effects: High rate of early removal of the device [6] [7]"}
{"id": "article-131512_69", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern", "content": "Other investigational procedures include the following: Bariatric arterial embolization, endoscopic ablation of duodenal mucosa, transoral gastroplasty, articular circular endoscopic stapler, endoscopic sclerotherapy, transoral endoscopic restrictive implant system, mucosal resurfacing, and gastric botulinum toxin A injection. These procedures are not ASBMS endorsed or FDA approved and remain investigational procedures, requiring IRB approval and not covered by insurance. [6] [7] [26] [27]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern. Other investigational procedures include the following: Bariatric arterial embolization, endoscopic ablation of duodenal mucosa, transoral gastroplasty, articular circular endoscopic stapler, endoscopic sclerotherapy, transoral endoscopic restrictive implant system, mucosal resurfacing, and gastric botulinum toxin A injection. These procedures are not ASBMS endorsed or FDA approved and remain investigational procedures, requiring IRB approval and not covered by insurance. [6] [7] [26] [27]"}
{"id": "article-131512_70", "title": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern", "content": "The role of combination therapy: Multiple studies have shown that combining two or more drugs or combining drug therapy with surgery/devices has additive action on weight loss. Some combinations are designed to shut off counterregulatory mechanisms which hamper weight loss. However, some of them are not yet ASBMS or FDA approved. Some combination therapies that have been studied include: Pramlintide+phentermine Amylin+bupropion-naltrexone GLP-1 agonists+glucagon GLP-1+PYY GLP-1+PYY+oxyntomodulin Exenatide+dapagliflozin Canagliflozin+phentermine Repeat intragastric balloon treatment RNYGB+endoscopic enhancement Intragastric balloon+liraglutide Endobarrier device+liraglutide GLP1+GIP+glucagon triple agonist Setmelanotide+liraglutide Cagrilintide+ semaglutide Pramlintide+metreleptin+calcitonin receptor agonist [8] [11] [28] [29] [30]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Issues of Concern. The role of combination therapy: Multiple studies have shown that combining two or more drugs or combining drug therapy with surgery/devices has additive action on weight loss. Some combinations are designed to shut off counterregulatory mechanisms which hamper weight loss. However, some of them are not yet ASBMS or FDA approved. Some combination therapies that have been studied include: Pramlintide+phentermine Amylin+bupropion-naltrexone GLP-1 agonists+glucagon GLP-1+PYY GLP-1+PYY+oxyntomodulin Exenatide+dapagliflozin Canagliflozin+phentermine Repeat intragastric balloon treatment RNYGB+endoscopic enhancement Intragastric balloon+liraglutide Endobarrier device+liraglutide GLP1+GIP+glucagon triple agonist Setmelanotide+liraglutide Cagrilintide+ semaglutide Pramlintide+metreleptin+calcitonin receptor agonist [8] [11] [28] [29] [30]"}
{"id": "article-131512_71", "title": "Non-Dieting Approaches to Treatment of Obesity -- Clinical Significance", "content": "Obesity due to caloric excess can be driven by a \"food addiction,\" similar to substance abuse, causing a persistent desire to overeat despite the consequences of excess food intake. [8] It is primarily for this reason that non-dieting approaches (such as cognitive behavioral therapy, pharmacotherapy, and bariatric surgery and devices) are essential to treat obesity. Many patients enroll and fail comprehensive diet and lifestyle programs primarily because weight loss maintenance requires participation for extended periods of time, which are costly and produce slow results. [1]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Clinical Significance. Obesity due to caloric excess can be driven by a \"food addiction,\" similar to substance abuse, causing a persistent desire to overeat despite the consequences of excess food intake. [8] It is primarily for this reason that non-dieting approaches (such as cognitive behavioral therapy, pharmacotherapy, and bariatric surgery and devices) are essential to treat obesity. Many patients enroll and fail comprehensive diet and lifestyle programs primarily because weight loss maintenance requires participation for extended periods of time, which are costly and produce slow results. [1]"}
{"id": "article-131512_72", "title": "Non-Dieting Approaches to Treatment of Obesity -- Clinical Significance", "content": "Generally, weight loss is curvilinear and reaches a plateau in 3 to 6 months, after which lifestyle interventions need to be continued to further the weight loss, else weight gain is imminent due to compensatory mechanisms that take over. [7] Thus, consistent and sustained weight loss with pharmacotherapy and bariatric surgery plays a vital role in patients' weight loss journey and should be considered early in the treatment course.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Clinical Significance. Generally, weight loss is curvilinear and reaches a plateau in 3 to 6 months, after which lifestyle interventions need to be continued to further the weight loss, else weight gain is imminent due to compensatory mechanisms that take over. [7] Thus, consistent and sustained weight loss with pharmacotherapy and bariatric surgery plays a vital role in patients' weight loss journey and should be considered early in the treatment course."}
{"id": "article-131512_73", "title": "Non-Dieting Approaches to Treatment of Obesity -- Other Issues -- New Drugs/Therapies Being Developed\u00a0to Tackle Obesity", "content": "These are not yet FDA-approved drugs but target parts of the hedonistic and homeostatic pathways in the peripheral and central nervous system to induce weight loss. They include tesofensine-a serotonin-noradrenaline-dopamine reuptake inhibitor, RNA inhibitor against RIP140, CDDO-imidazolide, antibodies against ghrelin, high dose systemic PYY antagonists, cetilistat-a gastric and pancreatic lipase inhibitor, beloranib-MetAP2 inhibitor, KD026-microsomal transfer protein inhibitor in the intestine, fecal microbiota transplant, bile acid receptors-TGR5, FXR, GSK1521498-selective mu-opioid receptor antagonist, PRX-07034-a 5-HT6 antagonist, SNAP-94847-MCH-1 antagonist, oxyntomodulin-a glucagon + GLP 1 agonist, ghrelin antagonist and vaccines, GIP receptor antagonist, monoacylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH)-appetite suppression-degradation of endocannabinoids anandamide, 2-arachidonic acid glycerol, a long-acting amylin analog, an FGF21 analog, licogliflozin-SGLT1 inhibitor, PYY 3-36 analog, oxytocin receptor agonist and a Type 4 FGF receptor antagonist. [9] [8] [11] [13] [31] [2]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Other Issues -- New Drugs/Therapies Being Developed\u00a0to Tackle Obesity. These are not yet FDA-approved drugs but target parts of the hedonistic and homeostatic pathways in the peripheral and central nervous system to induce weight loss. They include tesofensine-a serotonin-noradrenaline-dopamine reuptake inhibitor, RNA inhibitor against RIP140, CDDO-imidazolide, antibodies against ghrelin, high dose systemic PYY antagonists, cetilistat-a gastric and pancreatic lipase inhibitor, beloranib-MetAP2 inhibitor, KD026-microsomal transfer protein inhibitor in the intestine, fecal microbiota transplant, bile acid receptors-TGR5, FXR, GSK1521498-selective mu-opioid receptor antagonist, PRX-07034-a 5-HT6 antagonist, SNAP-94847-MCH-1 antagonist, oxyntomodulin-a glucagon + GLP 1 agonist, ghrelin antagonist and vaccines, GIP receptor antagonist, monoacylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH)-appetite suppression-degradation of endocannabinoids anandamide, 2-arachidonic acid glycerol, a long-acting amylin analog, an FGF21 analog, licogliflozin-SGLT1 inhibitor, PYY 3-36 analog, oxytocin receptor agonist and a Type 4 FGF receptor antagonist. [9] [8] [11] [13] [31] [2]"}
{"id": "article-131512_74", "title": "Non-Dieting Approaches to Treatment of Obesity -- Other Issues -- Caution About Dietary Supplements and Unproven Treatments for Weight Loss", "content": "Some advertised supplements available over the counter are not FDA-approved for weight loss and have not undergone rigorous testing and review to prove their efficacy or safety. These contain substances like green tea, caffeine, yohimbine, bitter orange, guar gum, glucomannan, pyruvate, chromium, and calcium. In addition, techniques like liposuction are typically sought for their aesthetic value but do not improve metabolic parameters or change insulin sensitivity and cannot reduce ectopic fat deposits, which influence cardiovascular outcomes. [7]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Other Issues -- Caution About Dietary Supplements and Unproven Treatments for Weight Loss. Some advertised supplements available over the counter are not FDA-approved for weight loss and have not undergone rigorous testing and review to prove their efficacy or safety. These contain substances like green tea, caffeine, yohimbine, bitter orange, guar gum, glucomannan, pyruvate, chromium, and calcium. In addition, techniques like liposuction are typically sought for their aesthetic value but do not improve metabolic parameters or change insulin sensitivity and cannot reduce ectopic fat deposits, which influence cardiovascular outcomes. [7]"}
{"id": "article-131512_75", "title": "Non-Dieting Approaches to Treatment of Obesity -- Enhancing Healthcare Team Outcomes", "content": "A motivated patient and an\u00a0interprofessional team consisting of physicians, bariatric surgeons, gastroenterologists, nurses, pharmacists, physical and exercise therapists, dieticians, and psychiatrists are the only way weight loss can be achieved sustainably and maintained appropriately. Non-dieting approaches to treating obesity with drug therapy, gastrointestinal devices, and bariatric surgery should be\u00a0offered early to patients, along with lifestyle modification. With interprofessional care coordination and counseling, patients will have a greater chance of achieving\u00a0therapeutic success. [Level 5]", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Enhancing Healthcare Team Outcomes. A motivated patient and an\u00a0interprofessional team consisting of physicians, bariatric surgeons, gastroenterologists, nurses, pharmacists, physical and exercise therapists, dieticians, and psychiatrists are the only way weight loss can be achieved sustainably and maintained appropriately. Non-dieting approaches to treating obesity with drug therapy, gastrointestinal devices, and bariatric surgery should be\u00a0offered early to patients, along with lifestyle modification. With interprofessional care coordination and counseling, patients will have a greater chance of achieving\u00a0therapeutic success. [Level 5]"}
{"id": "article-131512_76", "title": "Non-Dieting Approaches to Treatment of Obesity -- Enhancing Healthcare Team Outcomes", "content": "Patients and providers must consider obesity a chronic disease requiring chronic treatment. Primary care physicians must obtain a detailed history,\u00a0physical examination and run\u00a0basic laboratory tests to rule out other treatable causes of obesity, such as hypothyroidism and Cushing's syndrome. Family and friends must also motivate patients through their weight loss journeys, as these can sometimes be long and arduous.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Enhancing Healthcare Team Outcomes. Patients and providers must consider obesity a chronic disease requiring chronic treatment. Primary care physicians must obtain a detailed history,\u00a0physical examination and run\u00a0basic laboratory tests to rule out other treatable causes of obesity, such as hypothyroidism and Cushing's syndrome. Family and friends must also motivate patients through their weight loss journeys, as these can sometimes be long and arduous."}
{"id": "article-131512_77", "title": "Non-Dieting Approaches to Treatment of Obesity -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Non-Dieting Approaches to Treatment of Obesity -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}